Huzhou, Zhejiang, China | Fund Name | Location |
| 01 Advisors | California, San Francisco, United States |
| 301 Ventures | College Park, Maryland, United States |
| Alsea | Distrito Federal, Mexico, Mexico City |
| AZURE PLUS | Chiyoda, Japan |
| Beijing Performance & Arts Group | Beijing, Beijing, China |
| BF Holdings | Dudley, England, United Kingdom |
| Chengdu High-tech Zone Venture Angel Fund | Chengdu, China, Sichuan |
| CICC Healthcare Investment Fund | Beijing, Beijing, China |
| Flywheel Ventures | New Mexico, Santa Fe, United States |
| Fondo Italiano d'Investimento | Italy, Lombardy, Milan |
| Grey | New York, New York, United States |
| GSO Innovation | - |
| Highlander Venture Fund | - |
| Huazhu Hotels Group | China, Shanghai, Shanghai |
| Huilun Biological Technology | China, Shanghai |
| LSP | - |
| SaaS Venture Partners, LLC | California, Moraga, United States |
| Vangoo Investment Partners | Beijing, Beijing, China |
| Velcourt | - |
| Wong Fong Industries | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Jinmate | $61M | 17 May 2024 | Huzhou, Zhejiang, China | ||
Arthur Pharmaceuticals | 01 Feb 2023 | Jiaxing, Zhejiang, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Jinmate | $61M | 17 May 2024 | Huzhou, Zhejiang, China | ||
Arthur Pharmaceuticals | 01 Feb 2023 | Jiaxing, Zhejiang, China |
